Cancer Neoantigens

Malignant transformation of cells depends on accumulation of DNA damage. Over the past years we have learned that the T cell-based immune system frequently responds to the neoantigens that arise as a consequence of this DNA damage. Furthermore, recognition of neoantigens appears an important driver...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of immunology Vol. 37; p. 173
Main Authors: Schumacher, Ton N, Scheper, Wouter, Kvistborg, Pia
Format: Journal Article
Language:English
Published: United States 26.04.2019
Subjects:
Animals
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Autoantigens - genetics
Autoantigens - immunology
Cancer Vaccines - immunology
Epitopes, T-Lymphocyte - genetics
Epitopes, T-Lymphocyte - immunology
Humans
Immunity, Cellular
Immunotherapy, Adoptive - methods
Lymphocyte Activation
Neoplasms - immunology
Precision Medicine
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
checkpoint blockade
neoantigens
cancer
mutations
T cells
immunotherapy
ISSN:1545-3278, 1545-3278
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant transformation of cells depends on accumulation of DNA damage. Over the past years we have learned that the T cell-based immune system frequently responds to the neoantigens that arise as a consequence of this DNA damage. Furthermore, recognition of neoantigens appears an important driver of the clinical activity of both T cell checkpoint blockade and adoptive T cell therapy as cancer immunotherapies. Here we review the evidence for the relevance of cancer neoantigens in tumor control and the biological properties of these antigens. We discuss recent technological advances utilized to identify neoantigens, and the T cells that recognize them, in individual patients. Finally, we discuss strategies that can be employed to exploit cancer neoantigens in clinical interventions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1545-3278
1545-3278
DOI:10.1146/annurev-immunol-042617-053402